Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Genfit S.A. GNFT
$4.12
-$0.06 (-1.44%)
На 18:01, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
212546275.00000000
-
week52high
5.05
-
week52low
3.02
-
Revenue
20195000
-
P/E TTM
-9
-
Beta
0.93091600
-
EPS
-0.57000000
-
Last Dividend
0.00000000
-
Next Earnings Date
06 апр 2023 г. в 04:00
Описание компании
Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and with Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| SVB Leerink | Outperform | Outperform | 11 апр 2022 г. |
| HC Wainwright & Co. | Buy | Neutral | 20 дек 2021 г. |
| HC Wainwright & Co. | Neutral | Neutral | 30 сент 2021 г. |
| SVB Leerink | Outperform | Outperform | 05 апр 2021 г. |
| Stifel | Buy | Hold | 23 июл 2020 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
Genfit: Catching Strong Bid With Emerging Data (Technical Analysis)
Seeking Alpha
10 февр 2023 г. в 08:47
Genfit is a relatively low-beta play offering investors tactical upside with a potential re-rating to the upside. Investors have rewarded the company's pipeline assets to date, in addition to emerging data from its non-invasive technologies.
The 7 Best Biotech Stocks to Buy for February 2023
InvestorPlace
07 февр 2023 г. в 13:51
While unpredictable compared to other sectors due to the ebb and flow of clinical trials, the best biotech stocks to buy offer investors incredible upside opportunities. Better yet, the volatility largely centers on developments of the industry itself rather than the broader economy.
Genfit S.A.: A 'Sum Of The Parts' Story
Seeking Alpha
07 сент 2022 г. в 11:52
Today, we put France-based biotech concern Genfit S.A. back in the spotlight for the first time in a year and a half. The company has a lot of moving parts and little analyst coverage but seems to be advancing its pipeline forward.